7-chloro-1,N-dimethyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-1,N-dimethyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide
• 英文别名: 7-chloro-1-methyl-3-methylsulphamoyl-4-quinolone；7-chloro-N,1-dimethyl-4-oxoquinoline-3-sulfonamide
• 化学式: C₁₁H₁₁ClN₂O₃S
• 分子量: 286.739
• InChiKey: GWIZNOQICBSENV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Treatment of cardiovascular disease with quinolinone enantiomers
  申请人：R.T. Alamo Ventures I, L.L.C.

  公开号：US20020143031A1

  公开（公告）日：2002-10-03

  The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.

  本发明涉及用于治疗心血管疾病的组合物和方法。在一个优选实施例中，本发明考虑在未同时接受硝酸盐或硝酸酯治疗的受试者中使用氟斯奎南的对映体（以及含有氟斯奎南的配方）。
• Methods for the treatment of central nervous system disorders in certain patient groups
  申请人：R.T. Alamo Ventures I, LLC

  公开号：US20030130311A1

  公开（公告）日：2003-07-10

  Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明提供了用于治疗特定患者群体的中枢神经系统疾病的方法和组合物，包括但不限于抽动症。本发明的方法包括在没有心脏疾病和/或未接受有机硝酸酯的症状表现为中枢神经系统障碍的患者中利用含有喹啉酮（及其衍生物）的制药组合物。
• TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS
  申请人：R.T. Alamo Ventures I, L.L.C,

  公开号：US20020143030A1

  公开（公告）日：2002-10-03

  Methods for treating specific patient groups for gastroparesis are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives) in patients with symptoms of gastroparesis who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明提供了用于治疗特定患者群体的胃排空障碍的方法。本发明的方法包括在没有心脏疾病和/或未被给予有机硝酸酯的胃排空障碍症状患者中利用含有喹啉酮（和衍生物）的药物组合物。
• METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS
  申请人：R.T. Alamo Ventures I, L.L.C.

  公开号：US20020147215A1

  公开（公告）日：2002-10-10

  Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明提供了用于治疗特定患者群体的中枢神经系统疾病的方法和组合物，包括但不限于抽动症。本发明的方法包括利用含有喹诺酮（及其衍生物）的药物组合物治疗中枢神经系统疾病症状的患者，这些患者除心脏疾病外，未接受有机硝酸盐。
• Quinolones having antihypertensive activity
  申请人：The Boots Company PLC

  公开号：EP0206616A2

  公开（公告）日：1986-12-30

  Quinolines with antihypertensive activity have the general formula 1, wherein X is the residue of an optionally substituted benzene ring; R is lower alkyl; R3 is hydrogen or lower alkyl; R1 and R2, which may be the same or different, are hydrogen, lower alkyl, or, together with the nitrogen atom to which they are attached, form a 5 to 7 membered saturated heterocyclic ring optionally containing an additional hetero atom selected from nitrogen, oxygen and sulphur and optionally substituted by 1 or more lower alkyl groups; and the dotted line between positions 2 and 3 of the quinolone nucleus represents an optional bond. The compounds are useful as antihypertensive agents. They are also indicated for use in treating heart failure and ischaemic heart disease. With the exception of the three compounds 1-methyl-4--oxo-1,4-dihydroquinoline-3-sulphonamide, 1,N-dimethyl-4--oxo-1,4-dihydroquinoline-3-sulphonamide and 6,7-dimeth- oxyl-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, the quinolones of formula I are novel. Pharmaceutical compositions containing the compounds of formula I are described. Processes for preparing the novel quinolones are also described.

  具有抗高血压活性的喹啉类化合物具有通式 1、 其中，X 是任选取代的苯环的残基；R 是低级烷基；R3 是氢或低级烷基；R1 和 R2（可以相同或不同）是氢、低级烷基，或与它们连接的氮原子一起形成 5 至 7 个成员的饱和杂环，其中任选含有一个选自氮、氧和硫的杂原子，并任选被 1 个或多个低级烷基取代；喹诺酮核的位置 2 和 3 之间的虚线代表任选键。这些化合物可用作降压药。它们还可用于治疗心力衰竭和缺血性心脏病。 除了 1-甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺、1,N-二甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺和 6,7-二甲基-氧代-4-甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺这三种化合物外，式 I 中的喹诺酮类化合物均为新型化合物。 描述了含有式 I 化合物的药物组合物。还描述了制备新型喹诺酮类药物的工艺。